Figure 3.
Figure 3. Intention to treat analysis of results for 204 patients with CML-CP treated with imatinib at the Hammersmith Hospital in London.
 Reprinted with permission from de Lavallade et al.7
 PFS indicates progression-free survival; CHR, complete hematologic response; MCyR, major cytogenetic response; EFS, patients alive at 5 years in stable complete cytogenetic response (CCyR) and still on imatinib.

Intention to treat analysis of results for 204 patients with CML-CP treated with imatinib at the Hammersmith Hospital in London.
 Reprinted with permission from de Lavallade et al.7
 PFS indicates progression-free survival; CHR, complete hematologic response; MCyR, major cytogenetic response; EFS, patients alive at 5 years in stable complete cytogenetic response (CCyR) and still on imatinib.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal